BIOMARKERS IN DRUG DEVELOPMENT

A Handbook of Practice, Application, and Strategy

Edited by

MICHAEL R. BLEAVINS, Ph.D., DABT
Michigan Technology and Research Institute
Ann Arbor, Michigan

CLAUDIO CARINI, M.D., Ph.D., FRCPath
Fresenius Biotech of North America
Waltham, Massachusetts

MALLÉ JURIMA-ROMET, Ph.D.
MDS Pharma Services
Montreal, Quebec, Canada

RAMIN RAHBARI, M.S.
Innovative Scientific Management
New York, New York
BIOMARKERS IN DRUG DEVELOPMENT
CONTENTS

CONTRIBUTORS ix

PREFACE xv

PART I  BIOMARKERS AND THEIR ROLE IN DRUG DEVELOPMENT 1

1  Biomarkers Are Not New 3
   Ian Dews

2  Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care 15
   Gregory J. Downing

3  Enabling Go/No Go Decisions 31
   J. Fred Pritchard and Mallé Jurima-Romet

PART II  IDENTIFYING NEW BIOMARKERS: TECHNOLOGY APPROACHES 41

4  Imaging as a Localized Biomarker: Opportunities and Challenges 43
   Jonathan B. Moody, Philip S. Murphy, and Edward P. Ficaro

5  Protein Biomarker Discovery Using Mass Spectrometry-Based Proteomics 101
   Joanna M. Hunter and Daniel Chelsky

6  Quantitative Multiplexed Patterning of Immune-Related Biomarkers 121
   Dominic Eisinger, Ralph McDade, and Thomas Joos
CONTENTS

7 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity 135
Jason A. Sprowl and Amadeo M. Parissenti

8 Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Molecules 155
Douglas M. Molina, W. John W. Morrow, and Xiaowu Liang

PART III CHARACTERIZATION AND VALIDATION 177

9 Characterization and Validation Biomarkers in Drug Development: Regulatory Perspective 179
Federico Goodsaid

10 Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development 187
Jean W. Lee, Yuling Wu, and Jin Wang

11 Molecular Biomarkers from a Diagnostic Perspective 215
Klaus Lindpaintner

12 Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulation 231
Francis Kalush and Steven Gutman

13 Importance of Statistics in the Qualification and Application of Biomarkers 247
Mary Zacour

PART IV BIOMARKERS IN DISCOVERY AND PRECLINICAL SAFETY 287

14 Qualification of Safety Biomarkers for Application to Early Drug Development 289
William B. Mattes and Frank D. Sistare

15 Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitor 301
Alan P. Brown

16 Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequences 323
Claire Cornips and Huub Schellekens

17 New Markers of Kidney Injury 335
Sven A. Beushausen
PART V TRANSLATING FROM PRECLINICAL RESULTS TO CLINICAL AND BACK 359

18 Translational Medicine—A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers 361

19 Clinical Validation and Biomarker Translation 375
David Lin, Andreas Scherer, Raymond Ng, Robert Balshaw, Shawna Flynn, Paul Keown, Robert McMaster, and Bruce McManus

20 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis 399
Christina Trollmo and Lars Klareskog

21 Pharmacokinetic and Pharmacodynamic Biomarker Correlations 413
J.F. Marier and Keith Gallicano

22 Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints 433
Calvert Louden and Ruth A. Roberts

PART VI BIOMARKERS IN CLINICAL TRIALS 443

23 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: Case Study in Anticoagulant Development 445
Kay A. Criswell

24 Integrating Molecular Testing Into Clinical Applications 463
Anthony A. Killeen

25 Biomarkers for Lysosomal Storage Disorders 475
Ari Zimran, Candida Fratazzi, and Deborah Elstein

26 Value Chain in the Development of Biomarkers for Disease Targets 485
Charles W. Richard, III, Arthur O. Tzianabos, and Whaijen Soo

PART VII LESSONS LEARNED: PRACTICAL ASPECTS OF BIOMARKER IMPLEMENTATION 493

27 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork 495
Lena King, Mallé Jurima-Romet, and Nita Ichhpurani
CONTENTS

28 Integrating Academic Laboratories Into Pharmaceutical Development 515
Peter A. Ward and Kent J. Johnson

29 Funding Biomarker Research and Development Through the Small Business Innovative Research Program 527
James Varani

30 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices 541
Bruce D. Car, Brian Gemzik, and William R. Foster

31 Anti-Unicorn Principle: Appropriate Biomarkers Don’t Need to Be Rare or Hard to Find 551
Michael R. Bleavins and Ramin Rahbari

32 Biomarker Patent Strategies: Opportunities and Risks 565
Cynthia M. Bott and Eric J. Baude

PART VIII WHERE ARE WE HEADING AND WHAT DO WE REALLY NEED? 575

33 IT Supporting Biomarker-Enabled Drug Development 577
Michael Hehenberger

34 Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine 593
Craig P. Webb, John F. Thompson, and Bruce H. Littman

35 Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection 625
Heather Walmsley, Michael Burgess, Jacquelyn Brinkman, Richard Hegele, Janet Wilson-McManus, and Bruce McManus

36 Pathodynamics: Improving Biomarker Selection by Getting More Information from Changes Over Time 643
Donald C. Trost

37 Optimizing the Use of Biomarkers for Drug Development: A Clinician’s Perspective 693
Alberto Gimona

38 Nanotechnology-Based Biomarker Detection 709
Joshua Reineke

INDEX 731
CONTRIBUTORS

Salvatore Alesci, M.D., Ph.D., Wyeth Research, Collegeville, Pennsylvania

Robert Balshaw, Ph.D., Syreon Corporation, Vancouver, British Columbia, Canada

Eric J. Baude, Ph.D., Brinks Hofer Gilson & Lione, P.C., Ann Arbor, Michigan

Sven A. Beushausen, Ph.D., Pfizer Global Research and Development, Chesterfield, Missouri

Michael R. Bleavins, Ph.D., DABT, Michigan Technology and Research Institute, Ann Arbor, Michigan

Cynthia M. Bott, Ph.D., Honigman Miller Schwartz and Cohn LLP, Ann Arbor, Michigan

Jacquelyn Brinkman, M.Sc., University of British Columbia, Vancouver, British Columbia, Canada

Alan P. Brown, Ph.D., DABT, Pfizer Global Research and Development, Ann Arbor, Michigan

Michael Burgess, Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Bruce D. Car, B.V.Sc., Ph.D., Bristol-Myers Squibb Co., Princeton, New Jersey

Daniel Chelsky, Ph.D., Caprion Proteomics, Inc., Montreal, Quebec, Canada

Claire Cornips, B.Sc., Utrecht University, Utrecht, The Netherlands

Kay A. Criswell, Ph.D., Pfizer Global Research and Development, Groton, Connecticut

Ian Dews, MRCP, FFPM, Envestia Ltd., Thame, Oxfordshire, UK
Gregory J. Downing, D.O., Ph.D., U.S. Department of Health and Human Services, Washington, DC

Dominic Eisinger, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Deborah Elstein, Ph.D., Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel

Giora Z. Feuerstein, M.D., Wyeth Research, Collegeville, Pennsylvania

Edward P. Ficaro, Ph.D., INVIDIA Medical Imaging Solutions, Ann Arbor, Michigan

Shawna Flynn, B.Sc., Syreon Corporation, Vancouver, British Columbia, Canada

William R. Foster, Ph.D., Bristol-Myers Squibb Co., Princeton, New Jersey

Candida Fratazzi, M.D., Altus Pharmaceuticals, Inc., Waltham, Massachusetts

Keith Gallicano, Ph.D., Watson Laboratories, Corona, California

Brian Gemzik, Ph.D., Bristol-Myers Squibb Co., Princeton, New Jersey

Alberto Gimona, M.D., Merck Serono International, Geneva, Switzerland

Federico Goodsaid, Ph.D., Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Steven Gutman, M.D., M.B.A., University of Central Florida, Orlando, Florida; formerly with the U.S. Food and Drug Administration, Rockville, Maryland

Richard Hegele, M.D., Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Michael Hehenberger, Ph.D., IBM Healthcare & Life Sciences, Somers, New York

Joanna M. Hunter, Ph.D., Caprion Proteomics, Inc., Montreal, Quebec, Canada

Nita Ichhpurani, B.A., PMP, MDS Pharma Services, Mississauga, Ontario, Canada

Kent J. Johnson, M.D., The University of Michigan Medical School, Ann Arbor, Michigan

Thomas Joos, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Mallé Jurima-Romet, Ph.D., MDS Pharma Services, Montreal, Quebec, Canada
CONTRIBUTORS

Francis Kalush, Ph.D., U.S. Food and Drug Administration, Silver Spring, Maryland; formerly with USFDA, Rockville, Maryland

Paul Keown, M.D., D.Sc., MBA, University of British Columbia, Vancouver, British Columbia, Canada

Anthony A. Killeen, M.D., Ph.D., University of Minnesota, Minneapolis, Minnesota

Lena King, Ph.D., DABT, CanBioPharma Consulting, Inc., Guelph, Ontario, Canada

Lars Klareskog, M.D., Ph.D., Karolinska Institute, Stockholm, Sweden

Jean W. Lee, Ph.D., Amgen, Inc., Thousand Oaks, California

Xiaowu Liang, Ph.D., Antigen Discovery, Inc., Irvine, California

David Lin, B.MLSc., University of British Columbia, Vancouver, British Columbia, Canada

Klaus Lindpaintner, M.D., M.P.H., F. Hoffmann–La Roche AG, Basel, Switzerland

Bruce H. Littman, M.D., Translational Medicine Associates, Stonington, Connecticut

Calvert Louden, Ph.D., Johnson & Johnson Pharmaceuticals, Raritan, New Jersey

J.F. Marier, Ph.D., FCP, Pharsight, A Certara Company, Montreal, Quebec, Canada

William B. Mattes, Ph.D., DABT, The Critical Path Institute, Rockville, Maryland

Ralph McDade, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Bruce McManus, M.D., Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Robert McMaster, D.Phil., University of British Columbia, Vancouver, British Columbia, Canada

Douglas M. Molina, Ph.D., Antigen Discovery, Inc., Irvine, California

Jonathan B. Moody, Ph.D., INVIA Medical Imaging Solutions, Ann Arbor, Michigan

W. John W. Morrow, Ph.D., Antigen Discovery, Inc., Irvine, California

Philip S. Murphy, Ph.D., GlaxoSmithKline Research and Development, Uxbridge, Middlesex, UK
Raymond Ng, Ph.D., University of British Columbia, Vancouver, British Columbia, Canada
Amadeo M. Parissenti, Ph.D., Laurentian University, Sudbury, Ontario, Canada
J. Fred Pritchard, Ph.D., MDS Pharma Services, Raleigh, North Carolina
Ramin Rahbari, M.S., Innovative Scientific Management, New York, New York
Joshua Reineke, Ph.D., Wayne State University, Detroit, Michigan
Charles W. Richard, III, M.D., Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts
Ruth A. Roberts, Ph.D., AstraZeneca Research and Development, Macclesfield, UK
Robert R. Ruffolo, Jr., Ph.D., Wyeth Research, Collegeville, Pennsylvania
J. Lynn Rutkowski, Ph.D., Wyeth Research, Collegeville, Pennsylvania
Huub Schellekens, M.D., Utrecht University, Utrecht, The Netherlands
Andreas Scherer, Ph.D., Spheromics, Kontiolahti, Finland
Frank D. Sistare, Ph.D., Merck Research Laboratories, West Point, Pennsylvania
Whaijen Soo, M.D., Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts
Jason A. Sprowl, Ph.D., Laurentian University, Sudbury, Ontario, Canada
John F. Thompson, M.D., Helicos BioSciences, Cambridge, Massachusetts
Christina Trollmo, Ph.D., Karolinska Institute and Roche AB Sweden, Stockholm, Sweden
Donald C. Trost, M.D., Ph.D., Analytic Dynamics, Niantic, Connecticut
Arthur O. Tzianabos, Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts
James Varani, Ph.D., The University of Michigan Medical School, Ann Arbor, Michigan
Heather Walmsley, M.A., Lancaster University, Bailrigg, Lancaster, UK
Frank L. Walsh, Ph.D., Wyeth Research, Collegeville, Pennsylvania
Jin Wang, M.S., Amgen, Inc., Thousand Oaks, California
Peter A. Ward, M.D., The University of Michigan Medical School, Ann Arbor, Michigan
Craig P. Webb, Ph.D., Van Andel Research Institute, Grand Rapids, Michigan

Janet Wilson-McManus, M.T., B.Sc., University of British Columbia, Vancouver, British Columbia, Canada

Yuling Wu, Ph.D., Amgen, Inc., Thousand Oaks, California

Mary Zacour, Ph.D., BioZac Consulting, Montreal, Quebec, Canada

Ari Zimran, M.D., Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel